Enhancing the value of the sFlt-1/PlGF ratio for the prediction of preeclampsia: Cost analysis from the Belgian healthcare payers' perspective.
peer reviewed ; OBJECTIVE: To evaluate the economic impact of introducing the soluble fms-like tyrosine kinase (sFlt-1) to placental growth factor (PlGF) ratio test into clinical practice in Belgium for the prediction of preeclampsia (PE). STUDY DESIGN: We developed a one-year time-horizon decision tree model to evaluate the short-term costs associated with the introduction of the sFlt-1/PlGF test for guiding the management of women with suspected PE from the Belgian public healthcare payers' perspective. The model estimated the costs associated with the diagnosis and management of PE in pregn... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | journal article |
Erscheinungsdatum: | 2021 |
Schlagwörter: | Biomarkers / PGF protein / human / Placenta Growth Factor / EC 2.7.10.1 (FLT1 protein / human) / EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-1) / Belgium / Biomarkers/blood / Cost-Benefit Analysis / Female / Humans / Placenta Growth Factor/blood / Pre-Eclampsia/blood/diagnosis/economics / Pregnancy / Vascular Endothelial Growth Factor Receptor-1/blood / Cost savings / Preeclampsia / sFlt-1/PlGF ratio / Human health sciences / Reproductive medicine (gynecology / andrology / obstetrics) / Sciences de la santé humaine / Médecine de la reproduction (Gynécologie / andrologie / obstétrique) |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26585226 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://orbi.uliege.be/handle/2268/299181 |